Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences Inc.

In a report released today, Cory Kasimov from Evercore ISI maintained a Hold rating on Moderna, with a price target of $28.00. According to TipRank...

Evercore ISI Remains a Hold on Moderna (MRNA)

RBC Capital analyst Luca Issi reiterated a Hold rating on Moderna yesterday and set a price target of $25.00. The company’s shares closed yesterday...

RBC Capital Reaffirms Their Hold Rating on Moderna (MRNA)

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics announced the results of its 2025 Annual General Meeting, highlig...

Alterity Therapeutics Advances in Neurodegenerative Disease Treatment

Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics announced significant progress at its 2025 Annual General Meeting, ...

An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics has announced significant changes to its Board of ...

Alterity Therapeutics Announces Board Restructuring for Growth

The Vanguard S&P 500 ETF ($VOO) gained 0.36% on Wednesday, snapping a four-day slide. The ETF is also up 1.10% in pre-market trading today after Nv...

Vanguard S&P 500 ETF (VOO) Daily Update, 11/20/2025

Moderna ($MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year and over 85% in three...

Moderna Stock (MRNA) Faces a Cash Crunch Test as Analyst Day Arrives

Analysts fell to the sidelines weighing in on Cartesian Therapeutics (RNAC – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report) w...

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and Galmed Pharmaceuticals (GLMD)

The SPDR S&P 500 ETF Trust ($SPY) closed 0.02% lower on Friday. Volatility in the technology sector and concerns about a potential delay in Federal...

SPY ETF Daily Update, 11/14/2025

In a report released today, Martin Fan from Wedbush maintained a Buy rating on Cartesian Therapeutics, with a price target of $38.00. Fan covers th...

Wedbush Remains a Buy on Cartesian Therapeutics (RNAC)

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Hold rating on Cartesian Therapeutics, with a price target of $1...

Cantor Fitzgerald Sticks to Its Hold Rating for Cartesian Therapeutics (RNAC)

Moderna ( ($MRNA) ) has provided an update. On November 12, 2025, Moderna, Inc. held a Special Meeting of Shareholders where two proposals were app...

Moderna Approves Stock Option Exchange Program

The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alterity Therapeutics Limited has disclosed a notice from Regal Funds Mana...

Alterity Therapeutics Discloses Equity Derivative Positions

The SPDR S&P 500 ETF Trust ($SPY) gained 0.23% on Tuesday. A key factor that supported its performance today includes a “relief rally” spurred by h...

SPY ETF Daily Update, 11/11/2025

Chardan Capital analyst Keay Nakae maintained a Hold rating on Avidity Biosciences on November 7 and set a price target of $72.00. According to Tip...

Chardan Capital Reaffirms Their Hold Rating on Avidity Biosciences (RNA)

How is VOO stock faring? The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index ($SPX), is down 0.21% in pre-market trading today. The dip...

VOO ETF Daily Update, 11/11/2025

An update from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics presented promising data on ATH434 at the 36th Internati...

Alterity Therapeutics Reports Promising ATH434 Results in MSA Treatment

Analysts fell to the sidelines weighing in on Neumora Therapeutics, Inc. (NMRA – Research Report) and Moderna (MRNA – Research Report) with neutral...

Analysts Are Neutral on Top Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), Moderna (MRNA)

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Cartesian Therapeutics yesterday and set a price target of $40.00. Ear covers the Healt...

Mizuho Securities Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)

How is VOO stock faring? The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 (SPX), is up 0.10% in pre-market trading today, helped by a stro...

VOO ETF Daily Update, 11/6/2025

The SPDR S&P 500 ETF Trust ($SPY) gained 0.35% on Wednesday, primarily due to a stronger-than-expected ADP private payrolls report. Meanwhile, conc...

SPY ETF Daily Update, 11/5/2025

How is VOO stock faring? The Vanguard S&P 500 ETF&nbsp;($VOO), which tracks the S&P 500 (SPX), is down 0.20% in pre-market trading today. &nbsp;The...

VOO ETF Daily Update, 11/5/2025

The SPDR S&P 500 ETF Trust ($SPY) gained 0.19% on Monday. Key factors influencing the market today include comments from Fed officials dimming hope...

SPY ETF Daily Update, 11/3/2025

How is VOO stock faring? The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 (SPX), is up 0.43% in pre-market trading today, supported by str...

VOO ETF Daily Update, 11/3/2025

Alterity Therapeutics ( ($AU:ATH) ) has issued an announcement. Alterity Therapeutics has reported promising results from its ATH434 trials, indica...

Alterity Therapeutics Advances MSA Treatment with Promising ATH434 Trial Results

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining COVID-related revenues a...

Moderna Stock (MRNA) Surges 17% on Buyout Speculation ahead of Q3 Earnings

Cambium Networks, Purple Biotech, and Ernexa Therapeutics are the 3&nbsp;Penny Stocks&nbsp;to watch on October 30, 2025, based on&nbsp;TipRanks’ Pe...

3 Penny Stocks to Watch Now, 10/30/25

The SPDR S&P 500 ETF Trust ($SPY) gained 0.05% on Wednesday, fueled by optimism over artificial intelligence (AI) stocks, especially Nvidia ($NVDA)...

SPY ETF Daily Update, 10/29/2025

The SPDR S&P 500 ETF Trust ($SPY) gained 0.27% on Tuesday. Importantly, the ETF hit a new all-time high of $688.90 during the day. The upside was d...

SPY ETF Daily Update, 10/28/2025

In a report released today, Geoff Meacham from Citi downgraded Avidity Biosciences to a Hold, with a price target of $72.00. The company’s shares o...

Avidity Biosciences (RNA) was downgraded to a Hold Rating at Citi

In a report released today, Yanan Zhu from Wells Fargo maintained a Buy rating on Avidity Biosciences, with a price target of $75.00. The company’s...

Wells Fargo Reaffirms Their Buy Rating on Avidity Biosciences (RNA)

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna yesterday and set a price target of $25.00. The company’s shares closed yester...

Bernstein Sticks to Its Hold Rating for Moderna (MRNA)

Chardan Capital analyst Keay Nakae downgraded Avidity Biosciences to a Hold today and set a price target of $72.00. The company’s shares closed yes...

Avidity Biosciences (RNA) was downgraded to a Hold Rating at Chardan Capital

TransCode Therapeutics ( ($RNAZ) ) has provided an update. On October 27, 2025, TransCode Therapeutics amended and restated its Certificate of Desi...

TransCode Therapeutics Amends Preferred Stock Designation

How is VOO stock faring? The Vanguard S&P 500 ETF is up 1.28% in the past five days and 16.63% year-to-date.&nbsp; Fund Flows and Sentiment The VOO...

VOO ETF News, 10/27/2025

Avidity Biosciences ( ($RNA) ) has issued an announcement. On October 25, 2025, Avidity Biosciences announced a merger agreement with Novartis AG, ...

Avidity Biosciences Announces Merger with Novartis AG

Avidity Biosciences received a Hold rating and price target from Raymond James analyst Martin Auster today. The company’s shares closed last Friday...

Avidity Biosciences (RNA) was downgraded to a Hold Rating at Raymond James

Leerink Partners analyst Mani Foroohar reiterated a Sell rating on Moderna yesterday and set a price target of $12.00. The company’s shares closed ...

Moderna (MRNA) Receives a Sell from Leerink Partners

In a report released yesterday, Cory Kasimov from Evercore ISI maintained a Hold rating on Moderna, with a price target of $28.00. The company’s sh...

Evercore ISI Sticks to Its Hold Rating for Moderna (MRNA)

How is VOO stock faring? The Vanguard S&P 500 ETF is up 0.75% in the past five days and 15.68% year-to-date.&nbsp; Fund Flows and Sentiment The VOO...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RNA	$70.56	-0.13%	3.08M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RNA	$70.56	-0.1%	3.08M
3
4
5
6

RNA

RNA

Compare Stocks

Start Your Comparison

Get Avidity Biosciences Inc. Data in Excel

Get Avidity Biosciences Inc. Data in Excel